Correction to: Titers of SARS CoV-2 antibodies in cord blood of neonates whose mothers contracted SARS CoV-2 (COVID-19) during pregnancy and in those whose mothers were vaccinated with mRNA to SARS CoV-2 during pregnancy

Journal of Perinatology, Published online: 07 December 2021; doi:10.1038/s41372-021-01272-7Correction to: Titers of SARS CoV-2 antibodies in cord blood of neonates whose mothers contracted SARS CoV-2 (COVID-19) during pregnancy and in those whose mothers were vaccinated with mRNA to SARS CoV-2 during pregnancy
Source: Journal of Perinatology - Category: Perinatology & Neonatology Authors: Source Type: research

Related Links:

NEW BRUNSWICK, N.J., January 6, 2022 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced new results from the largest study to date on the durability of COVID-19 vaccines in the United States (U.S.), showing that a single shot of the Johnson &Johnson COVID-19 vaccine resulted in long-lasting protection for up to six months against COVID-19 breakthrough infections, hospitalizations, and intensive care unit (ICU) admissions. The study was sponsored by the Janssen Pharmaceutical Companies of Johnson &Johnson and conducted in partnership with the Department of Science-Aetion, Inc, and the Division of...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
There’s yet another colorful addition to the pandemic lexicon—“flurona”—but it doesn’t refer to a new variant or even a new condition. The made-up term describes simultaneous infection with both influenza and SARS-CoV-2, the virus that causes COVID-19. The two diseases do not combine to make some hybrid form of either virus, which makes “flurona” a bit of a fearmongering misnomer. But co-infection is becoming more common. Having COVID-19 and the flu at the same time has been a possibility since the beginning of the pandemic, but until now, rigorous safety precautions largely ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 healthscienceclimate Source Type: news
If viruses know no borders, they
 have an equal disdain for human holidays. On Thanksgiving 2021, Dr. Rochelle Walensky shut off her phone for about 45 minutes and placed the turkey on the dining table to enjoy the holiday meal with her husband and three sons. When she turned the phone back on, she found, among the messages that had piled up, warnings that SARS-CoV-2 had morphed into a potentially dangerous new variant, identified in South Africa. Health officials there predicted that what would become known as the Omicron variant was much better at spreading than previous variants, and Walensky knew it was only a matter...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized COVID-19 feature healthscienceclimate Magazine Source Type: news
MONDAY, Jan. 3, 2022 -- The best time during pregnancy to get a COVID-19 vaccine appears to be right now. A new study found that antibodies to the SARS-CoV-2 virus in nearly 1,400 women and their babies at the time of delivery didn ’t vary...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
NEW BRUNSWICK, N.J., December 30, 2021 – Johnson &Johnson (NYSE: JNJ) (the Company) today announced new preliminary results from the South African Phase 3b Sisonke study which showed that a homologous (same vaccine) booster shot of the Johnson &Johnson COVID-19 vaccine (Ad26.COV2.S) demonstrated 85 percent effectiveness against COVID-19-related hospitalization. The study, conducted by the South African Medical Research Council (SAMRC), showed that the Johnson &Johnson booster reduced the risk of hospitalization from COVID-19 among healthcare workers in South Africa after Omicron became the dominant varian...
Source: Johnson and Johnson - Category: Pharmaceuticals Tags: Innovation Source Type: news
We examined the association between timing of maternal vaccination and maternal and umbilical cord anti-spike levels using a rank sum test. The relationships between a prior history of SARS-CoV-2 infection and maternal and umbilical cord anti-spike IgG levels, and between a booster dose and maternal and umbilical cord anti-spike levels, were also evaluated using a rank sum test.RESULTS: We included data from 1,359 vaccinated pregnant women, including 20 women who received a booster dose, and 1,362 umbilical cord samples. Maternal anti-spike IgG levels were detectable at delivery regardless of timing of vaccination througho...
Source: Obstetrics and Gynecology - Category: OBGYN Authors: Source Type: research
The Biohit SARS-CoV-2 IgM/IgG antibody kit (Biohit Healthcare, Hefei, China) is a novel rapid immunochromatographic test for the qualitative detection of SARS-CoV-2 antibodies in human blood. It is intended to aid in identifying a prior infection within 20 minutes, can be obtained from capillary sampling, and was found to have a sensitivity and specificity of over 95% in the detection of antibodies two weeks after COVID-19 infection in a non-pregnant patient. Our aim was to assess the presence of antibodies at birth by the Biohit rapid test, in women vaccinated during pregnancy with the BNT162b2 mRNA COVID-19 Pfizer vaccine.
Source: American Journal of Obstetrics and Gynecology - Category: OBGYN Authors: Tags: Poster Session II Source Type: research
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in pregnancy is associated with a higher risk for severe morbidity and mortality when compared with infection in non-pregnant women of childbearing age. An increasing number of countries recommend immunization against SARS-CoV-2 in pregnant women. Recent studies provide preliminary and supportive evidence on safety, immunogenicity and effectiveness of coronavirus disease 2019 (COVID-19) vaccines in pregnant women; however, important knowledge gaps remain which warrant further studies. This collaborative consensus paper provides a review of the current l...
Source: Frontiers in Immunology - Category: Allergy & Immunology Source Type: research
This cohort study evaluates maternal and neonatal COVID-19 antibody levels at delivery after receipt of a messenger RNA (mRNA) COVID-19 vaccine during the second trimester of pregnancy.
Source: JAMA Pediatrics - Category: Pediatrics Source Type: research
AbstractPregnant and postpartum individuals are known to have an elevated risk of severe COVID-19 compared with their non-pregnant counterparts. Vaccination is the most important intervention to protect these populations from COVID-19-related morbidity and mortality. An added benefit of maternal COVID-19 vaccination is transfer of maternal immunity to newborns and infants, for whom a vaccine is not (yet) approved. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-specific binding and neutralizing antibodies are present in infant cord blood and breast milk following natural maternal infection and transfer of mate...
Source: Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy - Category: Drugs & Pharmacology Authors: Tags: REVIEW OF THERAPEUTICS Source Type: research
More News: COVID-19 | Perinatology & Neonatology | Pregnancy | SARS | Vaccines